U.S. Markets closed

FDA staff backs Acadia's drug to treat psychosis associated with Parkinson's disease

March 25 (Reuters) - U.S. Food and Drug Administration staff members said on Friday Acadia Pharmaceuticals Inc's drug to treat psychosis associated with Parkinson's disease was effective enough to warrant approval.

The drug, Nuplazid, is a new chemical compound and could be the first drug specifically approved in the United States for Parkinson's disease psychosis (PDP). (http://1.usa.gov/22KhOhV)

(Reporting by Natalie Grover and Arathy S Nair in Bengaluru; Editing by Chizu Nomiyama)